JP2022502450A - 原子量子クラスターの治療的使用 - Google Patents

原子量子クラスターの治療的使用 Download PDF

Info

Publication number
JP2022502450A
JP2022502450A JP2021517797A JP2021517797A JP2022502450A JP 2022502450 A JP2022502450 A JP 2022502450A JP 2021517797 A JP2021517797 A JP 2021517797A JP 2021517797 A JP2021517797 A JP 2021517797A JP 2022502450 A JP2022502450 A JP 2022502450A
Authority
JP
Japan
Prior art keywords
composition
aqc
cancer
cells
zero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502450A5 (https=
Inventor
ブセッタ フェルナンデス デイヴィッド
ドミンゲス プエンテ フェルナンド
アルトゥロ ロペス クインテラ マニュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Publication of JP2022502450A publication Critical patent/JP2022502450A/ja
Publication of JP2022502450A5 publication Critical patent/JP2022502450A5/ja
Priority to JP2024086007A priority Critical patent/JP2024122998A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021517797A 2018-09-26 2019-09-25 原子量子クラスターの治療的使用 Pending JP2022502450A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086007A JP2024122998A (ja) 2018-09-26 2024-05-28 原子量子クラスターの治療的使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18196959 2018-09-26
EP18196963 2018-09-26
EP18196959.3 2018-09-26
EP18196963.5 2018-09-26
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086007A Division JP2024122998A (ja) 2018-09-26 2024-05-28 原子量子クラスターの治療的使用

Publications (2)

Publication Number Publication Date
JP2022502450A true JP2022502450A (ja) 2022-01-11
JP2022502450A5 JP2022502450A5 (https=) 2022-09-26

Family

ID=68342935

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517797A Pending JP2022502450A (ja) 2018-09-26 2019-09-25 原子量子クラスターの治療的使用
JP2024086007A Pending JP2024122998A (ja) 2018-09-26 2024-05-28 原子量子クラスターの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086007A Pending JP2024122998A (ja) 2018-09-26 2024-05-28 原子量子クラスターの治療的使用

Country Status (11)

Country Link
US (1) US20220031740A1 (https=)
EP (1) EP3862109A2 (https=)
JP (2) JP2022502450A (https=)
KR (1) KR20210086606A (https=)
CN (2) CN113179632A (https=)
AU (2) AU2019349780B2 (https=)
BR (1) BR112021005775A2 (https=)
CA (1) CA3111915A1 (https=)
IL (1) IL281663A (https=)
MX (1) MX2021003566A (https=)
WO (1) WO2020065115A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524963A (ja) * 2020-05-09 2023-06-14 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507996A (ja) * 2005-08-03 2009-02-26 ユニバシダデ デ サンチャゴ デ コンポステラ 原子量子クラスター、その製造方法およびその使用方法
JP2011504459A (ja) * 2007-10-05 2011-02-10 ウニベルシダーデ デ サンティアゴ デ コンポステラ 抗菌剤及び殺生物剤としての原子量子クラスター（ａｑｃ）の使用
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
CN101486733B (zh) * 2009-03-09 2011-05-25 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
WO2015015301A2 (en) * 2013-07-31 2015-02-05 Palama Ilaria El Cancer therapy with silver nanoparticles
KR20210021306A (ko) * 2018-06-12 2021-02-25 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마 정제된 원자 양자 클러스터를 제조하는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507996A (ja) * 2005-08-03 2009-02-26 ユニバシダデ デ サンチャゴ デ コンポステラ 原子量子クラスター、その製造方法およびその使用方法
JP2011504459A (ja) * 2007-10-05 2011-02-10 ウニベルシダーデ デ サンティアゴ デ コンポステラ 抗菌剤及び殺生物剤としての原子量子クラスター（ａｑｃ）の使用
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACS APPLIED MATERIALS AND INTERFACES, vol. 6, no. 6, JPN7023002842, 2014, pages 4050 - 4056, ISSN: 0005372976 *
ACS NANO, vol. 10, no. 2, JPN7023002838, 2016, pages 2509 - 2520, ISSN: 0005372980 *
CANCER BIOLOGY AND MEDICINE, vol. 11, no. 2, JPN7023002840, 2014, pages 86 - 91, ISSN: 0005372978 *
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 27, no. 10, JPN7023002839, 2012, pages 642 - 651, ISSN: 0005372979 *
NANOSCALE, vol. 4, no. 24, JPN7023002841, 2012, pages 7632 - 7635, ISSN: 0005372977 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524963A (ja) * 2020-05-09 2023-06-14 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療
JP7595087B2 (ja) 2020-05-09 2024-12-05 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療

Also Published As

Publication number Publication date
MX2021003566A (es) 2021-08-16
AU2025238114A1 (en) 2025-10-23
WO2020065115A2 (es) 2020-04-02
BR112021005775A2 (pt) 2021-06-29
EP3862109A2 (en) 2021-08-11
CN113179632A (zh) 2021-07-27
AU2019349780A1 (en) 2021-03-25
WO2020065115A3 (es) 2020-05-22
US20220031740A1 (en) 2022-02-03
AU2019349780B2 (en) 2025-07-03
CA3111915A1 (en) 2020-04-02
JP2024122998A (ja) 2024-09-10
CN120053481A (zh) 2025-05-30
IL281663A (en) 2021-05-31
KR20210086606A (ko) 2021-07-08

Similar Documents

Publication Publication Date Title
Gamberi et al. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness
Karginova et al. Inhibition of copper transport induces apoptosis in triple-negative breast cancer cells and suppresses tumor angiogenesis
Narayana et al. Inorganic nanoparticle-based treatment approaches for colorectal cancer: recent advancements and challenges
Tian et al. CRLX101, a nanoparticle–drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF1α
JP2024122998A (ja) 原子量子クラスターの治療的使用
Rath et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer
Yu et al. Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics
Guo et al. Dual hypoxia-responsive supramolecular complex for cancer target therapy
JP2018508196A (ja) 抗老化化合物及びその使用
US10729669B2 (en) Compositions and methods for treating cancer
Ohman et al. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic
KR20190084291A (ko) 암 치료를 위한 제약 조성물 및 방법
US11573241B2 (en) Total cellular iron as a marker of cancer stem cells and uses thereof
Jian et al. Zeolitic imidazolate framework-based nanoparticles for the cascade enhancement of cancer chemodynamic therapy by targeting glutamine metabolism
CN102014891A (zh) 增加癌症患者存活时间的化合物的组合物和使用方法
Zhang et al. Dihydroartemisinin suppresses glioma growth by repressing ERRα-mediated mitochondrial biogenesis
US6689811B2 (en) Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers
WO2021208787A1 (zh) 用于筛选药物的靶标多肽和筛选方法
Wang et al. Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum
HK40057518A (en) Therapeutic uses of atomic quantum clusters
JP5435461B2 (ja) がん治療用の遊走阻害剤
US20210395752A1 (en) Vdac1 silencing molecules and use thereof
Huda et al. Anti-tumor activity of metformin in human epidermal growth factor receptor 2 positive breast cancer cells
US20240009212A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof
Xie et al. Quinolinol-platinum (II) complex suppresses survival and invasion of laryngeal cancer cells via targeting YESassociated protein expression.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260403